LifeSci Capital initiated coverage of Rapt Therapeutics (RAPT) with an Outperform rating and $31 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics: Promising Growth Potential with Innovative Immunology Developments
- RAPT Therapeutics trading resumes
- RAPT Therapeutics trading halted, volatility trading pause
- Rapt Therapeutics target adjusted to $27 from $6 at H.C. Wainwright
- RAPT Therapeutics Unveils Plans for RPT904 Development